Mr. Hugh MacNaught reports

VENTRIPOINT ISSUES OPTION GRANTS AND REPORTS EXERCISE OF OPTIONS

Ventripoint Diagnostics Ltd. is providing an update on options. On March 12, 2025, the corporation issued 500,000 option grants at 15 cents and 500,000 option grants at 20 cents to contractors to the corporation. These option grants vested over four months and had a term of two years. On June 2, 2025, the corporation issued two million option grants at 10 cents to employees, consultants and advisers. The option grants vested from immediately to over three years and had a term for two to 10 years. On June 12, 2025, the corporation 1,635,000 option grants at 10 cents to employees, consultants and advisers. The option grants vested from immediately to over three months and had a term for two years. None of the above option grants were awarded to directors of officers of the corporation.

Since the last update (see the news release dated Feb. 11, 2024), a total of 3,119,450 options were exercised with a weighted average price of approximately 11 cents per share for gross proceeds to the corporation of $356,385. In addition, 1,994,500 options expired. There are currently 13,100,750 option grants outstanding with exercise prices between 10 cents and 50 cents, with a weighted average exercise price of 20 cents, and 11,083,250 of these options have vested.

The corporation has approximately 3.5 million options available for future grants under the stock option plan as approved by shareholders at the last special and annual general meeting of the corporation. The corporation has approximately 166 million shares issued and outstanding.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI (magnetic resonance imaging). This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide the company's future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.